

GLOBAL VACCINATION SUMMIT



European
Commission



World Health
Organization

PANEL MEMBER BIOGRAPHIES ROUNDTABLE 2

“ The magic of science: boosting vaccine research, development and innovation ”

PANEL MEMBERS


- ▶ **PROFESSOR STEWART COLE**, *President, Pasteur Institute*
- ▶ **DR SOUMYA SWAMINATHAN**, *Chief Scientist World Health Organization*
- ▶ **DR RICHARD HATCHETT**, *CEO, Coalition for Epidemic Preparedness Innovations*
- ▶ **NANETTE COCERO**, *Vaccines Europe (Global President, Vaccines Pfizer Biopharmaceuticals Group)*
- ▶ **DR MICHAEL MAKANGA**, *Director, European & Developing Countries Clinical Trials Partnership*



PROFESSOR STEWART COLE

President, Pasteur Institute

Professor Stewart Cole is an international authority in microbiology and infectious diseases, notably tuberculosis and leprosy. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialized nations. He has published and patented extensively, and is the recipient of many national and international prizes, and distinctions. Professor Cole is a Fellow of the Royal Society, a member of the European Molecular Biology Organisation and the current President of the Institut Pasteur, Paris, France.



DR SOUMYA SWAMINATHAN

Chief Scientist, World Health Organization

Dr Soumya Swaminathan was most recently WHO's Deputy Director-General for Programmes. A paediatrician from India and a globally recognized researcher on tuberculosis and HIV, she brings with her 30 years of experience in clinical care and research and has worked throughout her career to translate research into impactful programmes. Dr Swaminathan was Secretary to the Government of India for Health Research and Director General of the Indian Council of Medical Research from 2015 to 2017. In that position, she focused on bringing science and evidence into health policy making, building research capacity in Indian medical schools and forging south-south partnerships in health sciences. From 2009 to 2011, she also served as Coordinator of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases in Geneva.

She received her academic training in India, the United Kingdom of Great Britain and Northern Ireland, and the United States of America, and has published more than 350 peer-reviewed publications and book chapters. She is an elected Foreign Fellow of the US National Academy of Medicine and a Fellow of all three science academies in India. She has previously been on several WHO and global advisory bodies and committees, including the WHO Expert Panel to Review Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property, the Strategic and Technical Advisory Group of the Global TB Department at WHO, and most recently was Co-Chair of the Lancet Commission on TB.



DR RICHARD J. HATCHETT

Chief Executive Officer, Coalition for Epidemic Preparedness Innovations (CEPI)

Richard J. Hatchett, MD, is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), a partnership of public, private, philanthropic and civil organizations that will finance and co-ordinate the development of vaccines against high priority public health threats and vaccine platform technologies to respond rapidly to emerging infectious diseases with pandemic or epidemic potential.

Prior to joining CEPI, Dr. Hatchett most recently served as acting Director of the U.S. Biomedical Advanced Research and Development Authority (BARDA), after serving for five years as BARDA's Chief Medical Officer and Deputy Director. At BARDA, Dr. Hatchett oversaw programs to develop medical countermeasures against chemical, biological, radiological and nuclear threats, pandemic influenza, and emerging infectious diseases and led or helped lead the development of vaccines, therapeutics, and diagnostics for a number of emerging viruses, including the H3N2v and H7N9 influenza viruses, MERS, Ebola, and Zika. Previously, Dr. Hatchett served on the White House Homeland Security Council under President George W. Bush and was a member of the White House National Security Staff under President Barack Obama. He is a recipient of the HHS Secretary's Award for Distinguished Service and a five-time recipient of the NIH Director's Merit Award.

A graduate of Vanderbilt University and the Vanderbilt University Medical School, he completed a residency in internal medicine at the New York Hospital – Cornell Medical Center and a fellowship in medical oncology at Duke University Medical Center.



NANETTE COCERO

Vaccines Europe, Global President, Vaccines, Pfizer Biopharmaceuticals Group

Nanette Cocero is the Global President of Pfizer Vaccines. In her role, Nanette is responsible for the development and delivery of innovative vaccines that address serious and life-threatening conditions, helping to protect communities around the world.

Nanette leads a global team of 1,500 colleagues and manages a diverse vaccines portfolio aimed at protecting lives at all stages, from infants to older adults. She and her team also partner with governments, civic organizations, and others in the biopharmaceutical industry to accelerate global public health progress. Nanette is Chair of the International Federation of Pharmaceuticals and Manufacturers Association (IFPMA) Vaccine CEO Steering Committee, advocating for policies and practices that will enable greater access and affordability to vaccines in low and middle income countries.

Nanette earned a Bachelor of Science degree in chemistry from Cornell University; a Ph.D. in pharmacology from the University of Pennsylvania; and an MBA from The Wharton Business School.



DR MICHAEL MAKANGA

Executive Director, European and Developing Countries Clinical Trials Partnership

Dr. Makanga, MD PhD FRCP, is a clinician-scientist with 26 years of professional experience of working on health and poverty-related infectious diseases in Africa and Europe. This includes 22 years of work experience on medical product development and clinical regulatory activities. He holds a Medical Degree from Makerere University, Uganda, a Master's Degree at the University of Liverpool, and a PhD Clinical Pharmacology at the Liverpool School of Tropical Medicine, United Kingdom. He is also a Fellow of the Royal College of Physicians of Edinburgh, Scotland.

He has served as Executive Director for EDCTP since January 2016. Before joining EDCTP, Dr Makanga was first in clinical practice and academia, and later clinical research and research management. He joined EDCTP in 2004 and has served in different management positions prior to his current appointment. Moreover, he has served in various scientific and policy advisory boards for international product development, philanthropic organisations, World Bank and pharmaceutical companies involved in developing medicinal products for poverty related and neglected diseases.